胶原蛋白填充剂入局者激增,三类注册证不再是稀缺资源

第一财经
Feb 13

“以前是没得选,现在是不知道怎么选。”有人用这句话来形容当前的胶原蛋白填充剂市场竞争现状。今年以来,奇璞生物、巨子生物这两家公司相继有胶原蛋白填充剂产品拿到医疗器械三类注册证。按照中国监管要求,玻尿酸、胶原蛋白、再生材料及其他新型注射材料需要获得国家药监局三类医疗器械注册证。从去年以来,共有9款胶原蛋白填充剂产品顺利拿到了三类注册证,这一数量超过了过去获批的总数。换言之,胶原蛋白三类注册证变得不...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10